Submit formulary exception for Part B vs D

If a Part B vs D payment determination cannot be made because prior-claim criteria are not met, submit a formulary exception through the formulary exception process to request Part D classification and coverage.

• Formulary exception required when absence of a prior claim prevents Part D payment classification.

Include prior-claim documentation within lookback windows

Provide documented prior pharmacy claims showing trials of the required formulary/generic agents within the stated look-back windows (120 or 365 days) when requesting Step 2 coverage for listed products.

• Look-back windows referenced include 120 days and 365 days depending on the product.
• Prior-claim evidence is required to satisfy step therapy prior-authorization criteria.

Show 25-day generic high‑intensity statin trial within 120 days

Document a prior 25-day trial of a formulary generic high-intensity statin (atorvastatin 40 or 80 mg OR rosuvastatin 20 or 40 mg) within the past 120 days before requesting Step 2 coverage for the listed high-intensity statin-related products; otherwise submit a step-exception request.

• Required trial duration: 25 days within the past 120 days.
• Acceptable agents: formulary generic atorvastatin (40/80 mg) or rosuvastatin (20/40 mg).

Provide two formulary generic triptan claims within 365 days

Before Step 2 coverage for dihydroergotamine (nasal), provide prior-claim evidence for two formulary generic triptans (for example sumatriptan and rizatriptan) within the past 365 days.

• Requirement: claims for 2 formulary generic triptans within 365 days.
• Example triptans listed: sumatriptan and rizatriptan.

No prior‑authorization text present in this segment

The provided document excerpts for these supply product sections enumerate affected items but do not specify any prior authorization requirement in the visible text; note that no PA language appears in these chunks.

• Sections list pen needles, syringes, and small wound-care supplies without explicit prior authorization instructions.

Product list only — no PA language present

This section lists affected supply products (pen needles, syringes, wound-care items) but the provided chunks do not contain any prior authorization instructions.

• Providers should be aware the excerpt is a product enumeration only; no PA rules are given here.

No prior‑authorization details — product names/sizes only

The excerpts enumerate product names and sizes for supply items; no prior authorization requirements are specified in these chunks.

• Content limited to listing affected product names and sizes without PA details.

Product list lacks PA instructions

The provided product list enumerates affected supply items but does not include any prior authorization requirements or instructions in the visible text.

• Providers should treat this as an affected‑products list; PA rules are not shown here.

Products affected — no PA text in excerpt

This excerpt contains a products‑affected list only; no prior authorization requirement statement is present in the provided chunks.

• Product enumeration is present, but PA language is absent in these sections.

No PA rules specified in this product list

The product listings in these chunks enumerate affected items but do not specify prior authorization rules; providers should note PA requirements are not detailed here.

• Only product listings are provided; no authorization criteria are visible.

Products affected — product listing only, no PA text

These chunks list products affected by the step therapy policy but do not include prior authorization requirements in the visible text; providers should reference the step therapy sections elsewhere for PA procedures.

• This is a products‑affected enumeration without explicit PA instructions.

Step therapy applies to listed insulin syringes and pen needles

Step therapy rules apply to the enumerated insulin syringes and pen needles; providers should expect prior-authorization/step‑therapy controls to apply to these listed supplies.

• Affected items include insulin syringes (0.3, 0.5, 1 mL) and pen needles across multiple gauges and lengths.

Product enumeration only — no PA details

This section is a product enumeration and does not provide prior authorization details; providers should not infer PA procedures from these chunks alone.

• Use the exact product descriptors when matching to affected items; PA details are absent here.

Products affected — supplies list without PA text

The provided segments list supplies affected by step therapy (insulin syringes, pen needles, alcohol prep pads, gauze) but do not contain explicit prior authorization text in the visible excerpts.

• These are catalog entries of affected supplies; no PA instructions included.

PA not specified — product lists only

These chunks enumerate affected products (insulin syringes and pen needles) but do not detail prior authorization requirements; providers should note PA is not specified here.

• Product lists are present; PA language is not provided in these excerpts.

Products affected — no PA text in provided segment

The excerpt lists affected insulin delivery and accessory products but provides no prior authorization text; confirm PA rules in the full policy when preparing requests.

• Chunks are product enumerations without PA criteria.

Products affected — no PA specified here

This part of the document enumerates affected supply products; no explicit prior authorization requirement is specified in these chunks.

• Providers must consult other policy sections for PA procedures; these chunks are product lists only.

Submit prior‑trial evidence for Step 2 products

Multiple products in the document are designated Step 2 and therefore require prior trials of specified formulary or generic alternatives as detailed in product-specific lines; ensure prior‑trial evidence is submitted for Step 2 requests.

• Many Step 2 entries require prior claims within 120 or 365 days depending on the product.
• Submit prior-claim documentation matching the product-specific 'Details' criteria.

Provide product‑specific prior trials as listed

For the various Step 2 products, provide the specific prior trials required per product details (e.g., two formulary generic antipsychotics within 365 days for certain antipsychotics; two generic triptans within 365 days for DHE nasal spray).

• Antipsychotics: claim for 2 formulary oral generics within past 365 days where specified.
• DHE nasal spray: prior claim for 2 formulary generic triptans within 365 days.
• Eslicarbazepine: prior claims for 2 generic anticonvulsants within 365 days.
• Fibrate/omega‑3: prior claim for generic fenofibrate within 120 days.

Match requests to enumerated step‑therapy supply list

When requesting coverage, reference the enumerated insulin syringes, pen needles, alcohol prep pads, and gauze listed as subject to step therapy to ensure the request matches an affected product.

• Affected categories include insulin syringes (various volumes and gauges), pen needles (multiple gauges/lengths), alcohol prep pads, and gauze bandages/pads.

Product enumeration without step‑order or failure criteria

The product chunks enumerate supplies subject to step therapy but do not provide the step sequence or failure criteria in the visible text; do not assume step order or durations from these lists alone.

• These chunks list affected products but lack step progression, required trials, or exception criteria.

Products listed for step therapy — no step rules provided here

Products are listed as subject to step therapy in these chunks, but the excerpts do not include the step rules or required prior trials; consult the detailed criteria elsewhere before submitting authorization requests.

• Providers must not rely on these product lists alone to determine prior‑therapy requirements.

Affected products — step therapy list lacks step logic

These chunks enumerate the affected products but do not define actionable step‑therapy progression or required failures; confirm criteria in the complete policy before filing PA requests.

• Listed items include many insulin syringes and pen needles; step logic not defined in these excerpts.

Reference exact product descriptors when requesting coverage

The document identifies specific insulin syringes and pen needles as subject to step therapy; when requesting coverage, reference the exact product descriptors (brand, gauge, volume, length) to match the affected items.

• Providers must use the exact product descriptors when applying step therapy rules.

Product list present — step rules not included here

This segment enumerates products affected by step therapy but does not include the step progression or failure criteria; do not assume required prior products or durations from these chunks alone.

• Consult the full policy for actionable step‑therapy requirements.

Listed devices included — no step rules in excerpt

The products listed are included under the step therapy listing, but the provided excerpts do not describe any step‑therapy logic or required prior trials; verify criteria in policy detail before submission.

• Listing alone does not convey required prior‑therapy actions.

Provide product name, gauge, and volume in requests

When requesting coverage under the step therapy policy for these supply products, include the product name, needle gauge, and syringe volume to match one of the listed affected SKUs.

• Required details: product name (brand), needle gauge and needle length, syringe volume (0.3, 0.5, or 1 mL) as applicable.

Product listing only — no PA or denial triggers shown

This product‑listing excerpt indicates affected items but contains no prior authorization or denial triggers in the visible text; do not infer denial criteria from these lists alone.

• These chunks are catalog entries; PA/denial logic is not present here.

Products listed for step therapy — no step order provided

Products are enumerated as subject to step therapy, but the excerpts do not include step order, required trial agents, or failure durations; obtain full criteria before determining coverage denial risk.

• Absence of step rules in these chunks means further policy review is needed for actionable steps.

Do not assume step rules from product lists

The provided product enumerations do not describe step‑therapy rules; providers should not assume the presence or absence of prior‑therapy requirements from these lists alone.

• Confirm required prior agents, look‑back windows, and failure criteria in the detailed policy sections.

Insulin syringes and pen needles listed — PA not shown

Insulin syringes and pen needles are enumerated as affected products in these chunks, but no explicit prior authorization language is present here; check the policy for PA/step therapy procedures.

• Listing indicates these SKUs are subject to the plan's step therapy requirements; PA instructions are not included in these excerpts.

Devices listed — no step‑therapy rules present

These chunks list insulin syringes and pen needles but do not define step rules; verify step‑therapy criteria and PA procedures in the complete policy before submitting requests.

• Do not rely on these product listings alone to determine required prior trials or documentation.

Document prior claims within specified look‑back windows

Provide documentation of prior claims for the relevant drugs/indications within the specified look‑back windows (e.g., 120 or 365 days) to support Step 2 or Part B vs D determinations.

• Document the date and agent of prior claims to demonstrate fulfillment of look‑back criteria.

Provide documented proof of prior trials

Include proof of prior pharmacy trials demonstrating the required formulary generic agent use within the stated look‑back periods (e.g., 365 or 120 days) to satisfy Step 2 criteria.

• Examples: two formulary generic triptan claims within 365 days for DHE nasal spray; prior claim for generic topiramate within 120 days for topiramate solution; 25‑day trial of generic high‑intensity statin within 120 days for statin‑related products.

Product‑level listing present — no documentation instructions given

This section enumerates product‑level items required to be considered under Step Therapy, but the provided chunks do not include instructions on what documentation to submit beyond product matching.

• Chunks are product catalogs; no specific documentation workflow is described here.

No explicit documentation instructions in these chunks

No explicit documentation requirements are specified in several product‑listing chunks; providers should follow general guidance to include prior‑claim evidence and exact product descriptors when submitting requests.

• When in doubt, include prior claims and exact product identifiers (brand, gauge, volume, length).

Antiulcer prior‑claim required or risk denial

Failure to show a prior claim for a generic formulary oral lansoprazole, esomeprazole magnesium capsules, rabeprazole, omeprazole, or pantoprazole within the past 120 days may trigger denial for the antiulcer agent products listed.

• Requirement: prior claim within 120 days for specified generic antiulcer agents.

Antipsychotic prior‑claim requirement — denial risk

Lack of a prior claim for one formulary oral antipsychotic within the past 120 days (or two formulary oral generics within the past 365 days where specified) may trigger denial for the listed antipsychotic formulations.

• Antipsychotic Step 2 criteria reference prior‑claim windows of 120 days (one agent) or 365 days (two agents) depending on the product.

Absence of qualifying prior claim may trigger Part B vs D process

If no prior claim for an indicated RA, psoriasis, or active polyarticular JIA drug within 120 days is found, a Part B vs D payment determination may require use of the formulary exception process before approval.

• Absence of qualifying prior claim affects Part D payment classification and necessitates formulary exception processing.

Missing prior‑claim evidence can lead to denial

Failure to show the required prior claim(s) for formulary generic agents within the specified look‑back periods (for example, two formulary generic agents within 365 days) may trigger denial of Step 2 product requests.

• Examples include two formulary generic triptans within 365 days or two generic anticonvulsants within 365 days for eslicarbazepine.

Eslicarbazepine requires two prior generic anticonvulsant claims or risk denial

For eslicarbazepine products, absence of documented prior claims for two generic anticonvulsant agents within the past 365 days may result in denial of coverage.

• Specified qualifying anticonvulsants include carbamazepine, divalproex, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproic acid, zonisamide, or lacosamide.

Product lists alone do not define PA/denial criteria

The product list chunks do not show explicit authorization or denial triggers; these are product enumerations only and do not define actionable PA/denial rules in the provided excerpts.

• Do not treat the product listings themselves as definitive PA or denial instructions.

No denial triggers in product‑listing segment

No explicit denial triggers are provided in these product‑listing chunks; the content is a catalog of affected products and does not include authorization or denial language.

• Coverage controls implied by listing should be confirmed in the full policy text.

Product listings do not include denial criteria here

These product lists enumerate affected items but do not include explicit authorization or denial criteria in the visible text; verify denial triggers elsewhere in the policy.

• Product enumeration without criteria cannot be used alone to determine denial risk.

Product lists lack authorization/denial language

No explicit authorization or denial triggers are present in these product‑listing chunks; providers should consult the detailed criteria sections for actionable rules.

• Listings are informational; do not assume PA/denial logic from them.

No PA or denial language in these chunks

No authorization or denial instructions are included in these chunks; they only enumerate affected products and do not convey actionable PA rules.

• Confirm PA and denial criteria in the full policy before acting on these product lists.

Product lists only — no authorization/denial criteria shown

No explicit authorization or denial criteria are present in these product‑listing chunks; treat them as a list of affected products only.

• Further policy sections contain the criteria for authorization and denial.

No denial triggers — products‑listed only; unlisted products may be denied

No explicit authorization or denial trigger language appears in these product‑listing chunks; they only list affected products.

• If a requested product is not among the listed affected products, coverage or step therapy denial could apply.

Product enumeration without PA/denial rules

Product listings here do not include explicit authorization or denial rules; verify coverage controls in the full policy documentation.

• Listings imply affected products but do not define PA procedures.

Listings imply controls but lack explicit denial triggers

These enumerated product lists may imply coverage controls but do not present explicit denial triggers in the provided chunks; consult policy details for actionable denial criteria.

• Product presence in the list identifies it as subject to step therapy, but denial rules are not specified here.

Product lists only — no denial criteria here

No explicit authorization or denial criteria are present in these chunks; the sections only list affected products and do not define denial triggers in the visible excerpts.

• Confirm denial conditions in the full criteria sections before determining coverage outcome.

No denial triggers specified in these product lists

These product lists do not specify denial triggers; they enumerate affected supplies without defining authorization or denial rules in the provided text.

• Providers should not infer denial criteria from product-only chunks.

Product listing without denial logic

The product lists are catalog entries only and do not include explicit authorization or denial criteria in the visible text; check the full policy for applicable denial rules.

• Product presence indicates subjectivity to step therapy but does not state denial logic here.

No explicit documentation requirements in these chunks

No explicit documentation instructions are described in these chunks; they are primarily product catalogs. When submitting requests, include prior‑claim evidence and exact product identifiers per other detailed criteria.

• Include dates and agent names for prior claims and full product descriptors (brand, gauge, volume).